https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46791 Wed 30 Nov 2022 13:21:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43490 Wed 28 Sep 2022 10:57:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24881 Wed 11 Apr 2018 12:10:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34992 Wed 10 Jun 2020 11:54:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55096 Wed 10 Apr 2024 08:45:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55144 Tue 16 Apr 2024 09:45:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52399 Tue 10 Oct 2023 18:07:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35993 Thu 23 Jan 2020 14:49:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54270 Thu 15 Feb 2024 14:31:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31269 Sat 24 Mar 2018 08:44:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20771 vs as-needed 1·05, 0·92–1·20). We recorded no difference between treatment groups for time to recovery (adjusted p=0·79). Adherence to regular tablets (median tablets consumed per participant per day of maximum 6; 4·0 [IQR 1·6–5·7] in the regular group, 3·9 [1·5–5·6] in the as-needed group, and 4·0 [1·5–5·7] in the placebo group), and number of participants reporting adverse events (99 [18·5%] in the regular group, 99 [18·7%] in the as-needed group, and 98 [18·5%] in the placebo group) were similar between groups. Interpretation: Our findings suggest that regular or as-needed dosing with paracetamol does not affect recovery time compared with placebo in low-back pain, and question the universal endorsement of paracetamol in this patient group.]]> Sat 24 Mar 2018 08:00:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20056 Sat 24 Mar 2018 08:00:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18942 Sat 24 Mar 2018 07:58:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30098 Sat 24 Mar 2018 07:37:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27393 Sat 24 Mar 2018 07:34:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23405 Sat 24 Mar 2018 07:13:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46608 P = 0.76; joint modelling CACE 0.23 [-0.16 to 0.62] P = 0.24; intention-to-treat 0.11 [-0.20 to 0.42] P = 0.49; per protocol 0.29 [-0.07 to 0.65] P = 0.12); results for secondary outcomes and for exploratory analyses were similar. Paracetamol is ineffective for acute LBP even for patients who comply with treatment. This reinforces the notion that management of acute LBP should focus on providing patients advice and reassurance without the addition of paracetamol.]]> Mon 28 Nov 2022 08:58:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52344 50 years of age versus > 70 years of age) across different studies, as this has previously been shown to influence results.]]> Mon 09 Oct 2023 14:57:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55344 Fri 17 May 2024 15:50:55 AEST ]]>